慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

The company’s initiation of a pivotal Phase 3 study for DNTH103 in treating chronic inflammatory demyelinating polyneuropathy (CIDP) is a significant step, with the potential to establish DNTH103 as a ...

A retrospective cohort study was done on 134,698 individuals enrolled in a US healthcare database from 1988 to 1995. The database consists of integrated pharmacy and medical claims from six ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

导读历经数十年的探索与发展，多发性硬化（MS）治疗已取得长足进步。早期启动高效疾病修饰治疗（DMT），实现无疾病活动证据（NEDA）是目前国内外指南一致推荐的MS治疗理念与目标。早期高效策略，是通往MS治愈之路的第一步。然而对于初始未接受高效治疗的M ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

导读多发性硬化（MS）是一种免疫介导的中枢神经系统炎性脱髓鞘疾病。近年来，随着国内外指南共识的更新，以及多种疾病修饰治疗（DMT）药物的研发和应用，MS的标准化诊疗水平得以显著提升。然而，我国MS管理仍面临着诊断延迟、DMT药物治疗率和规范化随访率低 ...

The Amsterdam-based firm markets Vyvgart, a prescription medicine indicated for neurological conditions, generalized ...